Statistical tests based on new composite hypotheses in clinical trials reflecting the relative clinical importance of multiple endpoints quantitatively

Biometrical Journal

Volumn 51, Issue 5, 2009, Pages 749-762

  Nishikawa, Masako ^a,b   Tango, Toshiro ^a   Ohtaki, Megu ^b  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Composite endpoint; Multiple endpoints; One sided tests; Relative clinical weights; Superiority

Indexed keywords

MEDICAL APPLICATIONS;

CLINICAL TRIAL; COMPOSITE ENDPOINT; COMPOSITE HYPOTHESIS; CONTINUOUS VARIABLES; CONTROL TREATMENTS; MULTIPLE ENDPOINT; NON-INFERIORITY; ONE-SIDED TEST; RELATIVE CLINICAL WEIGHT; SUPERIORITY;

STATISTICAL TESTS;

ARTICLE; ASTHMA; BIOASSAY; BIOMETRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; FORCED EXPIRATORY VOLUME; HUMAN; METHODOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; STATISTICS;

ASTHMA; BIOMETRY; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; FORCED EXPIRATORY VOLUME; HUMANS; MODELS, STATISTICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 73949140515     PISSN: 03233847     EISSN: 15214036     Source Type: Journal    
DOI: 10.1002/bimj.200800190     Document Type: Article

References (25)

1. Alsaeedi, A., Sin, D. D. and McAlister, F. A. (2002). The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A systematic review of randomized placebo-controlled trials. The American Journal of Medicine 113, 59-65.
2. Berger, R. L. (1982). Multiparameter hypothesis testing and acceptance sampling. Technometrics 24, 295-300.
3. Bloch, D. A., Lai, T. L., Su, Z. and Tubert-Bitter, P. (2007). A combined superiority and non-inferiority approach to multiple endpoints in clinical trials. Statistics in Medicine 26, 1193-1207.
4. Bloch, D. A., Lai, T. L. and Tubert-Bitter, P. (2001). One-sided tests in clinical trials with multiple endpoints. Biometrics 57, 1039-1047.
5. Bristol, D. R. (2005). Superior safety in non-inferiority trials. Biometrical Journal 47, 75-81.
6. Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C. and Vestbo, J., for the TORCH investigators. (2007). Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine 356, 775-789.
7. Chow, S. C., Shao, J. and Wang, H. (2003). Sample Size Calculations in Clinical Research. Marcel Dekker, Inc., New York.
8. Committee for Medicinal Products for Human Use (CHMP). (2005). Guideline on the choice of the non-inferiority margin. Doc. Ref. EMEA/CPMP/EWP/2158/99. European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use.
9. Follmann, D. (1995). Multivariate tests for multiple endpoints in clinical trials. Statistics in Medicine 14, 1163-1175.
10. International Conference on Harmonization (ICH) of Technical Requirements for Regulations of Pharmaceuticals for Human use. (1998). ICH Tripartite Guideline E-9 Document, Statistical Principles for Clinical trials, 5 February 1998.
11. Jennison, C. and Turnbull, B. W. (1993). Group sequential tests for bivariate response: Interim analyses of clinical trials with both efficacy and safety endpoints. Biometrics 49, 741-752.
12. Läuter, J. (1996). Exact t and F test for analyzing studies with multiple endpoints. Biometrics, 52, 964-970. Erratum: Biometrics 56, 324-325.
13. Lloyd, D. F. (1999). Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflection upon hypothesis testing. Controlled Clinical Trials 20, 16-39.
14. O'Brien, P. C. (1984). Procedures for comparing samples with multiple endpoints. Biometrics 40, 1079-1087.
15. Perlman, M. D. and Wu, L. (2004). A note on one-sided tests with multiple endpoints. Biometrics 60, 276-280.
16. Pocock, S. J., Geller, N. L. and Tsiatis, A. A. (1987). The analysis of multiple endpoints in clinical trials. Biometrics 43, 487-498.
17. Röhmel, J., Gerlinger, C., Benda, N. and Läuter, J. (2006). On testing simultaneously non-inferiority in two multiple primary endpoints and superiority in at least one of them. Biometrical Journal 48, 916-933.
18. Senn, S. (1989). The consultant forum. Combining outcome measure: statistical power is irrelevant. Biometrics 45, 1027-1028.
19. Sutherland, E. R., Allmers, H., Ayas, N. T., Venn, A. J. and Martin, R. J. (2003). Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 58, 937-941.
20. Sozu, T., Kanou, T., Hamada, C. and Yoshimura, I. (2006). Power and sample size calculations in clinical trials with multiple primary variables. Japanese Journal of Biometrics 27, 83-96.
21. Tamhane, A. C. and Logan, B. R. (2004). A superiority-equivalence approach to one-sided tests on multiple endpoints in clinical trials. Biometrika 91, 715-727.
22. Tang, D. I., Gnecco, C. and Geller, N. L. (1989a). Design of group sequential clinical trials with multiple endpoints. Journal of the American Statistical Association 84, 776-779.
23. Tang, D. I., Gnecco, C. and Geller, N. L. (1989b). An approximate likelihood ratio test for a normal mean vector with nonnegative components with applications to clinical trials. Biometrika 76, 577-583.
24. Tubert-Bitter, P., Bloch, D. A. and Raynauld, J. P. (1995). Comparing the bivariate effects of toxicity and efficacy of treatments. Statistics in Medicine 14, 1129-1141.
25. Xiong, C., Yu, K., Gao, F., Yan, Y. and Zhang, Z. (2005). Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial. Clinical Trials 2, 387-393.